"Hydroxychloroquine is effective in oral lichen planus: A multicenter, randomized, controlled trial"

作者全名："Xie, Yulang; Xu, Hao; Li, Chunlei; Wang, Yufeng; Lu, Rui; Hua, Hong; Tang, Guoyao; Zhou, Gang; Jin, Xin; Shang, Qianhui; Dan, Pan; Zhang, Chengli; Luo, Xiaobo; Dan, Hongxia; Zeng, Xin; Zhou, Yu; Chen, Qianming"

作者地址："[Xie, Yulang; Xu, Hao; Shang, Qianhui; Dan, Pan; Zhang, Chengli; Luo, Xiaobo; Dan, Hongxia; Zeng, Xin; Zhou, Yu; Chen, Qianming] Sichuan Univ, Chinese Acad Med Sci, Res Unit Oral Carcinogenesis & Management, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis,, Chengdu, Peoples R China; [Li, Chunlei; Hua, Hong] Peking Univ, Sch & Hosp Stomatol, Dept Oral Med, Beijing, Peoples R China; [Wang, Yufeng; Tang, Guoyao] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Oral Med, Shanghai, Peoples R China; [Tang, Guoyao] Natl Clin Res Ctr Stomatol, Shanghai Key Lab Stomatol, Shanghai, Peoples R China; [Tang, Guoyao] Natl Clin Res Ctr Stomatol, Shanghai Res Inst Stomatol, Shanghai, Peoples R China; [Zhou, Gang] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hub, Wuhan, Peoples R China; [Jin, Xin] Chongqing Med Univ, Coll Stomatol, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China; [Zhou, Yu; Chen, Qianming] Sichuan Univ, 14 3rd Sect Ren Min Nan Rd, Chengdu 610041, Sichuan, Peoples R China"

通信作者："Zhou, Y; Chen, QM (通讯作者)，Sichuan Univ, 14 3rd Sect Ren Min Nan Rd, Chengdu 610041, Sichuan, Peoples R China."

来源：ORAL DISEASES

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001077734800001

JCR分区：Q1

影响因子：2.9

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：clinical trial; hydroxychloroquine; oral lichen planus

摘要："Objectives: This study was aimed to evaluate the safety and benefit of short-term application of hydroxychloroquine in the management of atrophic/erosive/ulcerative oral lichen planus (OLP).Methods: This multicenter, randomized, controlled, evaluator-blinded, prospective clinical trial was performed from October 1, 2019, to September 1, 2022. A total of 99 patients were randomized to receive systemic use of hydroxychloroquine (n = 50), or topical use of 0.05% dexamethasone (n = 49) for 4 weeks. The response to both treatment modalities was evaluated according to reticulation, hyperemic, and ulceration (RHU) score and visual analog scale (VAS) score.Results: After 4 weeks of medication, both groups showed substantial reduction in RHU and VAS score (p < 0.05). In hydroxychloroquine group, the average of RHU score was reduced from 10.60 to 7.68 (dropped 27.49%), and the average of VAS score was reduced from 3.74 to 2.47 (dropped 34.09%). There were no differences between the two groups in reduction of RHU score and VAS score (p > 0.05). Single factor analysis found hyperemic area (p = 0.019) and erosive/ulcerative area (p = 0.024) had impacts on drug efficacy of hydroxychloroquine, and logistic regression revealed that no factors (p > 0.05) influenced its efficacy.Conclusion: These findings indicate hydroxychloroquine is a safe and effective agent in treating atrophic/erosive/ulcerative OLP."

基金机构："This work was supported by grants from National Natural Science Foundation of China (No. 81730030 amp; No. 81771081), the CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-004), Fund of Sichuan Provincial Department of Science and Technology (2 [81730030, 81771081]; National Natural Science Foundation of China [2019-I2M-5-004]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2022YFS0039]; Fund of Sichuan Provincial Department of Science and Technology [LCYJ2023-DL-2]; Research and Develop Program, West China Hospital of Stomatology, Sichuan University; State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University and Peking Universit"

基金资助正文："This work was supported by grants from National Natural Science Foundation of China (No. 81730030 & No. 81771081), the CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-004), Fund of Sichuan Provincial Department of Science and Technology (2022YFS0039), and the Research and Develop Program, West China Hospital of Stomatology, Sichuan University (LCYJ2023-DL-2). The funding agencies had no role in the study design, collection, analysis, or interpretation of data, writing of the report, or the decision to submit the article for publication. The clinical study received service support funding from State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University and Peking University Hospital of Stomatology."